RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study (IMAGE)

Dana-Farber Cancer Institute

RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study

Caption

Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, is a lead investigator on a pancreatic cancer study with data published in The New England Journal of Medicine.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Kindly credit Dana-Farber Cancer Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.